Now covering 6,500 public companies · updated every earnings cycle

Financial journalism on the companies others ignore.

In-depth reporting on 6,500 small cap public companies — including almost 4,000 with no mainstream coverage. Permanently indexed. Free to read.

Try Blue Bird (BLBD) or Cal-Maine Foods (CALM)

What we publish

Seven types of coverage.

Original journalism across every stage of a company's story — from the first profile to same-day earnings coverage and daily market briefings.

Company Profile

A comprehensive introduction to a company's business, financials, and competitive position. The foundation of every company's coverage on Quarterlytics.

Foundation

Pre-Earnings Briefing

Published before a company reports. Covers what to expect, what management guided for, and which metrics matter most for the upcoming quarter.

Before results

Earnings Report

Published within 24 hours of results. Reports what the company delivered, what management said on the call, and what changed in the business narrative.

Within 24 hours

News Update

Same-day reporting on material developments between earnings cycles — acquisitions, CEO changes, guidance revisions, and significant filings.

Same day

Narrative Update

A periodic look at what a company is saying about itself — and whether that story has changed. Tracks management's language, strategic commitments, and insider activity.

Periodic

Sector Briefing

A quarterly landscape report on an entire sector. What drove performance, which companies stood out, and what to watch next quarter.

Quarterly

Morning Briefing

Published every trading day before the market opens. Market snapshot, overnight developments, today's earnings calendar, and the story of the day from the coverage universe.

Daily · Free
6,500 companies covered
4,000 with zero prior coverage
55,000+ annual reports indexed
Daily publishing cadence
The coverage gap

Four thousand companies nobody writes about.

Roughly 60% of US-listed companies have no consistent sell-side or press coverage. We close that gap with original reporting on the micro- and small-caps the market overlooks, sourced entirely from public filings and earnings calls.

Read more about Quarterlytics
Industrial facility
Don't miss

Latest Coverage

View all coverage →
Company Profile
Neuroprotection on Trial: Immunic's Campaign to Prove the Other Half of MS Matters
For three decades, multiple sclerosis treatment has been dominated by a single idea: stop the relapses, stop the disease. That approach built a $25 billion mark…
IMUX Jun 19, 2026
Company Profile
A Single Store in the Arizona Desert: Inside Sportsman's Warehouse's Make-or-Break Turnaround
Sportsman's Warehouse spent four years moving backward — not a single year of positive comparable-store sales from 2021 through 2024. Now CEO Paul Stone is bett…
SPWH Jun 19, 2026
Company Profile
DMC Global at a portfolio crossroads: balance sheet progress amid deteriorating operations
On DMC Global’s Q4 2025 earnings call, CEO James O’Leary put it plainly: the company is proud of its sharply lower net debt and disappointed in almost everythin…
BOOM Jun 19, 2026
Company Profile
Heron Therapeutics’ High-Wire Act: Can a Fast-Growing Acute Care Franchise Outrun Its Balance Sheet Risk?
In early 2026, Heron Therapeutics is running two races at once: accelerating adoption of its hospital-focused Acute Care drugs while its legacy oncology busines…
HRTX Jun 19, 2026
Company Profile
Exagen’s autoimmune bet: Can a fast‑growing niche diagnostics player turn scale into durability?
On Exagen’s Q1 2026 earnings call, CEO John Aballi pointed to record first‑quarter revenue and share gains in a $2.2 billion autoimmune testing market where the…
XGN Jun 19, 2026
Company Profile
Aldeyra Therapeutics: Can a RASP-Based Ocular Strategy Bridge the Gap to Revenue?
When Aldeyra Therapeutics won FDA acceptance for two eye-disease drug applications on the same March 2023 day, management framed the event as validation of a lo…
ALDX Jun 19, 2026
Company Profile
SunPower’s second act: Can Rodgers’ rebuilt residential-solar platform grow fast enough to outrun its balance sheet?
On SunPower’s Q1 2026 call, CEO T.J. Rodgers walked investors through a quarter that missed revenue guidance by 9%, produced a wider operating loss, and trigger…
SPWR Jun 19, 2026
Company Profile
Equillium’s Immunology Bet: Can Cash and a Narrow Pipeline Bridge the Gap to Revenue?
Four consecutive quarters of zero revenue, a cash balance that has quintupled in nine months, and a lead drug edging through late-stage trials: Equillium, Inc. …
EQ Jun 19, 2026
Company Profile
Health Catalyst at a breaking point: can an AI-first pivot offset shrinking revenue and deep losses?
On paper, Health Catalyst’s first quarter of 2026 looks anything but strong: revenue is slipping, gross margins have compressed, and GAAP losses have ballooned …
HCAT Jun 19, 2026
Company Profile
Corbus Pharmaceuticals after lenabasum: can a wounded cannabinoid bet become a diversified immunology platform?
When lenabasum failed two high-profile studies in 2020, Corbus Pharmaceuticals went from a single-asset systemic sclerosis story to a case study in biotech rein…
CRBP Jun 19, 2026